|
Induction of Apoptosis in K562 Leukemia Cells Upon Exposure to a Derivative from 4-aryl-4H Chromenes Family
|
M.H. Naseri1   , S. Hesami Tackallou2 , M. Mahdavi * 3, M.A. Moosavi4 , S. Abasalti4 , A. Foroumadi5 , A. Hadizade6 |
1- Alborz University of Medical Sciences, Karaj, Iran
2- Department of Biology, Islamic Azad University, Garmsar Branch, Garmsar, Iran
3- Department of Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran , mahdavi@gmail.com
4- Department of Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran
5- Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
6- Baqiyatallah, University of Medical Sciences, Tehran, Iran |
|
|
Abstract: (12975 Views) |
| Objective: It has been recently reported the activity of 4-aryl-4H-chromenes family to induce apoptosis in human cancer cells. Herein we report a derivative of 4-aryl-4H-chromene compound with higher apoptotic activity against Chronic Myelogenous Leukemia K562. The cells were seeded in 24-well plates at 1×105 cells/well and treated with 5-30 nM of the 2-amino-4-(3-bromo 4,5 dimethoxy-phenyl) -3-cyano -7-(dimethylamino) -4H-chromene (3-BMPC). This compound was found to be highly active growth inhibitor with IC50 of 10±3.1 nM as determined by MTT assay. Proliferation of K562 cells was diminished by more than 80% and viability was decreased by about 50% upon 96 h of treatment with 30 nM concentration of the compound. Apoptosis as the mechanism of cell death was investigated morphologically by Hoechst 33258 staining, as well as the formation of DNA ladder. K562 cells underwent apoptosis upon a single dose (at IC50 value) of the compound. These data further suggest that 3-BMPC may provide a novel therapeutic approach for the treatment of leukemia. |
|
| Keywords: Apoptosis, 4-aryl-4H-chromenes, Chronic Myelogenous Leukemia |
|
|
Full-Text [PDF 345 kb]
(3647 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2012/08/26 | Accepted: 2017/08/23 | Published: 2017/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
